<DOC>
	<DOCNO>NCT01571583</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness telaprevir combination Peg-IFN-alfa-2a ribavirin stable liver transplant patient chronic hepatitis C virus ( HCV ) genotype 1 .</brief_summary>
	<brief_title>An Efficacy Safety Study Telaprevir Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multicenter study genotype 1 chronic HCV infect liver transplant patient treat 12 week telaprevir 750 mg every 8 hour give combination Peg-IFN-alfa-2a ribavirin follow 36 week treatment Peg-IFN-alfa-2a ribavirin alone . The total treatment duration 48 week . Safety evaluate throughout study include evaluation adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>First time liver transplant recipient whose primary pretransplant diagnosis chronic hepatitis C genotype 1 More 6 month 10 year postliver transplant Patient receive treatment HCV prior liver transplantation Patient must agree liver graft biopsy screen period unless biopsy within three month screen period ( patient 6 month one year post transplant ) within six month screen period ( patient one year post transplant ) A female patient childbearing potential nonvasectomized male patient female partner childbearing potential must agree use 2 effective method birth control screen 6 month ( female patient ) 7 month ( male patient ) last dose ribavirin Patient currently infect coinfected HCV another genotype genotype 1 Patient receive treatment hepatitis C follow liver transplantation Patient history decompensated liver disease show evidence significant liver disease addition hepatitis C Patient human immunodeficiency virus hepatitis B virus coinfection Patient active malignant disease history malignant disease within past 5 year ( exception treat basal cell carcinoma hepatocellular carcinoma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chronic HCV infection</keyword>
	<keyword>Genotype 1 chronic HCV</keyword>
	<keyword>Liver transplantation</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hep C</keyword>
	<keyword>HCV</keyword>
	<keyword>Telaprevir</keyword>
	<keyword>Pegylated-Interferon-alfa-2a</keyword>
	<keyword>Ribavirin</keyword>
</DOC>